Display options
Cite
König E, Nicoletti A, Pattaro C, et al. Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease. Sci Rep. 2021;11(1):19582doi: 10.1038/s41598-021-99393-8.
König, E., Nicoletti, A., Pattaro, C., Annesi, G., Melotti, R., Gialluisi, A., Schwienbacher, C., Picard, A., Blankenburg, H., Pichler, I., Modugno, N., Ciullo, M., Esposito, T., Domingues, F. S., Hicks, A. A., Zappia, M., & Pramstaller, P. P. (2021). Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease. Scientific reports, 11(1), 19582. https://doi.org/10.1038/s41598-021-99393-8
König, Eva, et al. "Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease." Scientific reports vol. 11,1 (2021): 19582. doi: https://doi.org/10.1038/s41598-021-99393-8
König E, Nicoletti A, Pattaro C, Annesi G, Melotti R, Gialluisi A, Schwienbacher C, Picard A, Blankenburg H, Pichler I, Modugno N, Ciullo M, Esposito T, Domingues FS, Hicks AA, Zappia M, Pramstaller PP. Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease. Sci Rep. 2021 Oct 01;11(1):19582. doi: 10.1038/s41598-021-99393-8. PMID: 34599261; PMCID: PMC8486836.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2021 Oct 01;11(1):19582. doi: 10.1038/s41598-021-99393-8.

Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease.

Scientific reports

Eva König, Alessandra Nicoletti, Cristian Pattaro, Grazia Annesi, Roberto Melotti, Alessandro Gialluisi, Christine Schwienbacher, Anne Picard, Hagen Blankenburg, Irene Pichler, Nicola Modugno, Marina Ciullo, Teresa Esposito, Francisco S Domingues, Andrew A Hicks, Mario Zappia, Peter P Pramstaller

Affiliations

  1. Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Via Luigi Galvani 31, 39100, Bozen/Bolzano, Italy.
  2. Section of Neurosciences, Department G.F. Ingrassia, University of Catania, Catania, Italy.
  3. Institute for Biomedical Research and Innovation, National Research Council, Mangone (Cosenza), Italy.
  4. Mediterranean Neurological Institute (MNI), IRCCS Neuromed, Pozzilli, Italy.
  5. Institute of Genetics and Biophysics "Adriano Buzzati-Traverso", National Research Council, Naples, Italy.
  6. Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Via Luigi Galvani 31, 39100, Bozen/Bolzano, Italy. [email protected].

PMID: 34599261 PMCID: PMC8486836 DOI: 10.1038/s41598-021-99393-8

Abstract

Levodopa is the standard long-term dopamine replacement therapy to treat Parkinson's disease (PD) symptoms. With time, levodopa may induce debilitating dyskinesias (LID), the treatment of which represents a large clinically unmet need. However, time-to-LID onset varies between patients, reflecting a possible genetic component. We performed an hypothesis-free whole-exome sequencing (WES)-based screening of time-to-LID onset and attempted replication of previously published candidate gene studies. A WES association analysis was carried out in 134 PD patients in a meta-analytical framework. Replication was attempted in an independent study of 97 PD patients. Variants from previously reported candidate genes (OPRM1, COMT, BDNF) were also specifically examined. We significantly replicated, for the first time, an association of variant rs1799971 in the OPRM1 gene with time-to-LID onset. Furthermore, we identified two novel potentially functional variants, in the MAD2L2 (rs2233019) and MAP7 (rs35350783) genes, which were significantly associated at the discovery stage. In the replication study, the two variants showed direction-consistent effects but did not achieve the replication significance threshold. Our study provides the first WES results for time-to-LID onset, where we replicate association at OPRM1, and suggest new variants in MAD2L2 and MAP7 genes that are significant in discovery, but require larger datasets for replication. The results are being made publicly available to allow for independent external validation.

© 2021. The Author(s).

References

  1. Mov Disord. 2012 Jan;27(1):132-5 - PubMed
  2. Arch Neurol. 1999 Jan;56(1):33-9 - PubMed
  3. Neurol Sci. 2010 Feb;31(1):47-52 - PubMed
  4. Front Cell Neurosci. 2015 Sep 09;9:343 - PubMed
  5. Mov Disord. 2006 May;21(5):654-9 - PubMed
  6. Cell Death Dis. 2018 Jul 26;9(8):818 - PubMed
  7. Bioinformatics. 2010 Sep 1;26(17):2190-1 - PubMed
  8. Nature. 2015 May 28;521(7553):537-540 - PubMed
  9. J Mol Neurosci. 2017 Jun;62(2):244-254 - PubMed
  10. Neurodegener Dis. 2014;13(1):24-8 - PubMed
  11. Alcohol Clin Exp Res. 2009 Mar;33(3):383-93 - PubMed
  12. Prog Neurobiol. 2015 Sep;132:96-168 - PubMed
  13. Epidemiology. 2011 Jul;22(4):450-6 - PubMed
  14. Neuroinformatics. 2017 Jul;15(3):297-300 - PubMed
  15. J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):141-4 - PubMed
  16. J Neurosci. 2020 Aug 26;40(35):6812-6819 - PubMed

Publication Types